Few regulatory topics have generated more confusion in the research-compound community this year than the 2026 “peptide reclassification.” Headlines have declared peptides “legal again,” vendors have implied that long-restricted compounds are now cleared, and a great deal of the commentary has blurred two entirely separate regulatory worlds: the compounding-pharmacy framework that governs prescription preparations, and…

Semaglutide is a long-acting glucagon-like peptide-1 receptor (GLP-1R) analog that has become one of the most heavily referenced compounds in metabolic receptor pharmacology. As a structurally optimized GLP-1 analog, it has generated an extensive published mechanistic literature spanning receptor binding, intracellular signaling, and in-vitro cellular models — making it a frequent reference compound for laboratories…

Almost every research-peptide listing on the market now carries the phrase “third-party tested.” The phrase has become so common that it has stopped meaning very much. A certificate of analysis is only as good as the laboratory that produced it, the methods that laboratory ran, and whether anyone outside the vendor can confirm the document…

GHK-Cu is the copper(II) complex of the naturally occurring tripeptide glycyl-L-histidyl-L-lysine (GHK). First isolated from human plasma in 1973, it is among the longest-studied peptides in matrix biology, with a preclinical literature spanning five decades of fibroblast, gene-expression, and tissue-remodeling research. That depth of published work — combined with the compound’s distinctive copper chemistry —…

BPC-157 is a synthetic pentadecapeptide derived from a partial sequence of a protective protein identified in human gastric juice. Over three decades of preclinical literature — a PubMed search now returns more than one hundred peer-reviewed publications — have made it one of the most frequently referenced compounds in cytoprotection, angiogenesis, and tissue-repair research models.…

Tirzepatide (LY3298176) is a dual GLP-1/GIP receptor agonist developed by Eli Lilly that has become one of the most researched metabolic pathway compounds of the past three years. As one of the most-studied incretin-agonist research molecules, tirzepatide has generated substantial published pharmacological and mechanistic data — making it one of the most referenced compounds…

Verification standards, pricing comparison, and what COA documentation should look like when sourcing retatrutide.

HPLC, LC-MS, endotoxin testing explained. How to use ILS Labs and Janoshik public verification portals. Red flags to avoid.

What the Peptide Sciences shutdown revealed about supplier evaluation and what researchers need from a replacement vendor.

Mechanism, receptor binding, preclinical data and research applications for the most advanced triple agonist in active clinical investigation.